Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries

June 9, 2026 updated by: David Crandall, Henry Ford Health System
The goal of this study is to determine of one of three different devices to perform goniotomy to treat glaucoma at the time of cataract surgery is more or less effective than the others. The primary outcomes are to compare intraocular pressure control and glaucoma medication use up to 6 months after surgery. Participants will under combined cataract surgery and goniotomy. They will have post-operative follow up visits at 1 day, 1 week, 1 month, 3 months, and 6 month

Study Overview

Study Type

Interventional

Enrollment (Estimated)

132

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Michigan
      • Detroit, Michigan, United States, 48202
        • Henry Ford Health
        • Contact:
        • Contact:
        • Sub-Investigator:
          • Nauman Imami, MD
        • Sub-Investigator:
          • Paul Baciu, MD
        • Sub-Investigator:
          • Brian Florek, MD
        • Sub-Investigator:
          • Uma Jasty, MD
        • Sub-Investigator:
          • Melisa Nika, MD
        • Sub-Investigator:
          • Salma Noorulla, MD
        • Sub-Investigator:
          • Candice Yousif, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria: Adults ≥ 18 years old

  • Diagnosed with primary or secondary open-angle glaucoma (e.g., POAG, pigmentary, pseudoexfoliative)
  • Scheduled for phacoemulsification with planned goniotomy
  • Able to provide informed consent

Exclusion Criteria:

  • Angle-closure glaucoma

    • Prior glaucoma surgery in the study eye
    • Planned stand-alone goniotomy
    • Inability to comply with follow-up schedule

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: SION
Goniotomy performed with SION
Goniotomy opens the trabecular meshwork to lower intraocular pressure.
Active Comparator: BANG
Goniotomy performed with bent needle
Goniotomy opens the trabecular meshwork to lower intraocular pressure.
Active Comparator: Tanito
Goniotomy performed with Tanito hook
Goniotomy opens the trabecular meshwork to lower intraocular pressure.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intraocular pressure
Time Frame: up to 6 months
Eye pressure as measured by Goldmann applanation tonometry in mmHg
up to 6 months
Medications
Time Frame: up to 6 months
number of medications to control intraocular pressure
up to 6 months
Visual Acuity
Time Frame: up to 6 months
Measure of visual at each visit on Snellen acuity chart
up to 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: David A Crandall, MD, Henry Ford Health

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

July 1, 2026

Primary Completion (Estimated)

March 1, 2028

Study Completion (Estimated)

March 1, 2028

Study Registration Dates

First Submitted

January 15, 2026

First Submitted That Met QC Criteria

February 11, 2026

First Posted (Actual)

February 18, 2026

Study Record Updates

Last Update Posted (Actual)

June 11, 2026

Last Update Submitted That Met QC Criteria

June 9, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

There will be a publication based on the results of the study. We will not be sharing individual participant data outside of our institution and all collected data will be kept on a secured drive within the Henry Ford Health System.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Primary Open Angle Glaucoma (POAG)

Clinical Trials on Goniotomy

Subscribe